Adriamycin-Kombinations-Chemotherapie mit oder ohne Immunstimulation durch Corynebacterium parvum beim metastasierenden Mammakarzinom

Autor:	W. M. Gallmeier, H. J. Senn, R. Becher, D. Fritze, P. Drings, U. Bruntsch, A. C. Mayr, M. Kaufmann, U. Kempgens, W. Queißer
Rok vydání:	1979
Předmět:	Oncology medicine.medical_specialty Cyclophosphamide business.industry General Medicine Gastroenterology Corynebacterium parvum Fluorouracil Tumour size Internal medicine Remission duration medicine Methotrexate Remission rate business Median survival medicine.drug
Zdroj:	DMW - Deutsche Medizinische Wochenschrift. 104:1739-1743
ISSN:	1439-4413 0012-0472
DOI:	10.1055/s-0028-1129182
Popis:	In a randomised, multicentre study the effect of changing the combined cytostatic treatment with VAC (vincristin, adriamycin, cyclophosphamide) to FMC (fluorouracil, methotrexate, cyclophosphamide) was tested, as well as the effect of active non-specific immune stimulation with Corynebacterium parvum, and compared with a control group. In 59 of 120 patients (49%) in whom the results could be analysed there was a measurable significant regression of tumour size to less than 50% of its initial value. The course was stabilized in a further 43 (36%) women. Further tumour-growth progression or death in the early phase of treatment occurred in only 18 women (15%). Average remission was 16 months. Median survival time from start of the study in all analysable patients averaged 22 months. Patients with an ulcer at the site of application of Corynebacterium parvum had a clearly prolonged survival time. In all, immune stimulation with Corynebacterium parvum was no better, either with regard to the remission rate, remission duration or survival time.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b23ffe195a40e39d4062dfb5684e5d8b https://doi.org/10.1055/s-0028-1129182 Zobrazit plný text záznamu